Pfizer Inc. $PFE Shares Sold by M&G PLC

M&G PLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 13.6% in the 2nd quarter, HoldingsChannel reports. The firm owned 630,454 shares of the biopharmaceutical company’s stock after selling 99,650 shares during the quarter. M&G PLC’s holdings in Pfizer were worth $15,131,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jupiter Asset Management Ltd. lifted its position in shares of Pfizer by 10.0% in the 2nd quarter. Jupiter Asset Management Ltd. now owns 1,725,979 shares of the biopharmaceutical company’s stock valued at $41,838,000 after acquiring an additional 156,952 shares in the last quarter. SBI Securities Co. Ltd. grew its holdings in shares of Pfizer by 15.0% during the second quarter. SBI Securities Co. Ltd. now owns 419,629 shares of the biopharmaceutical company’s stock valued at $10,172,000 after buying an additional 54,578 shares in the last quarter. Westbourne Investment Advisors Inc. lifted its stake in Pfizer by 20.2% in the 2nd quarter. Westbourne Investment Advisors Inc. now owns 23,810 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 4,000 shares in the last quarter. Advyzon Investment Management LLC grew its stake in Pfizer by 34.2% during the 2nd quarter. Advyzon Investment Management LLC now owns 18,715 shares of the biopharmaceutical company’s stock valued at $454,000 after acquiring an additional 4,774 shares in the last quarter. Finally, Tiemann Investment Advisors LLC increased its holdings in shares of Pfizer by 8.6% in the 2nd quarter. Tiemann Investment Advisors LLC now owns 10,050 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 800 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 1.3%

PFE opened at $25.84 on Thursday. The business has a 50 day moving average of $24.77 and a 200-day moving average of $24.42. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $146.92 billion, a price-to-earnings ratio of 13.75, a P/E/G ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on PFE shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. Bank of America raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Morgan Stanley decreased their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Finally, Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.18.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.